Palleon Pharmaceuticals is Drug Discovery in United States that focus on biotechnology platform business. Founded in 2015. They cover business area such as operator, glycoimmune checkpoint inhibitor, cancer, technology, insight, scientific leader, glycoscience, human immunology, multiple immune cell type, physician, rational combination therapy, resistance, first-generation immuno-oncology agent.
2015
( 11 years old in 2026 )
Biotechnology Platform
-
266 Second Avenue
Waltham, MA 02451
United States
Private
operatorglycoimmune checkpoint inhibitorcancertechnologyinsightscientific leaderglycosciencehuman immunologymultiple immune cell typephysicianrational combination therapyresistancefirst-generation immuno-oncology agent
* We use standard office opening hours in near Palleon Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Palleon Pharmaceuticals is Drug Discovery business from United States that founded in 2015 (11 years old in 2026), Palleon Pharmaceuticals business is focusing on Biotechnology Platform.
Palleon Pharmaceuticals headquarter office and corporate office address is located in 266 Second Avenue Waltham, MA 02451 United States.
Palleon Pharmaceuticals was founded in United States.
In 2026, Palleon Pharmaceuticals is currently focus on biotechnology platform sector.
Above is snippet of Google Trends for "biotechnology platform" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Palleon Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
